A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

NCT04895345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: TQB2450
RADIATION: Intensity modulated radiotherapy

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.